TNK or Tenecteplase

Best Practices for Tenecteplase in Acute Ischemic Stroke

Tenecteplase is a clot-dissolving medication used to treat eligible patients with an acute ischemic stroke, meaning a stroke caused by a blocked blood vessel. It should only be administered through an established stroke protocol by clinicians trained in acute stroke evaluation and treatment.

The American Heart Association/American Stroke Association supports either tenecteplase or alteplase for eligible patients treated within the standard 4½-hour thrombolysis window. Tenecteplase is given as one IV bolus, which may simplify and speed treatment compared with an hour-long alteplase infusion.

Act Quickly

Treatment should begin as soon as possible after the patient arrives. Do not delay treatment in an otherwise eligible patient while waiting for symptoms to improve.

Important early steps include:

• Activate the stroke team immediately.
• Determine the patient’s last-known-well time.
• Complete a focused neurological assessment.
• Check blood glucose.
• Obtain an accurate body weight.
• Complete emergency brain imaging to rule out bleeding.
• Review medications, recent procedures and bleeding risks.
• Evaluate for large-vessel occlusion without delaying thrombolytic treatment.

For eligible patients with a disabling neurological deficit, treatment should not be withheld only because the NIH Stroke Scale score is low.

Confirm That the Stroke Is Ischemic

Tenecteplase should not be administered until brain imaging has ruled out intracranial bleeding.

The treatment team should also consider whether the patient’s symptoms may be caused by another condition, such as:

• Low blood sugar
• Seizure
• Migraine
• Medication effects
• Infection
• Another neurological condition

Testing should be completed quickly and should not create unnecessary treatment delays.

Recommended Stroke Dose

For acute ischemic stroke, tenecteplase is dosed according to body weight and administered as a single IV bolus over five seconds. The maximum stroke dose is 25 mg.

The stroke dose is much lower than the tenecteplase dose used for a heart attack. Stroke systems should use separate order sets, dosing cards and medication-safety checks to reduce the risk of a dosing error.

Treatment Window

The FDA prescribing information directs administration as soon as possible and within three hours after stroke symptoms begin. The 2026 American Heart Association/American Stroke Association guideline supports tenecteplase as an option within the broader 4½-hour thrombolysis window for otherwise eligible patients.

Selected patients with an unknown time of onset or a later presentation may qualify for thrombolysis based on advanced brain imaging. These cases should follow current stroke guidelines, specialist recommendations and the hospital’s approved protocol.

Blood-Pressure Management

Blood pressure must be measured accurately before treatment and monitored closely during and after tenecteplase administration.

The stroke team should follow its current thrombolysis protocol for:

• Blood-pressure eligibility before treatment
• Medication used to lower blood pressure when needed
• Monitoring frequency
• Blood-pressure goals during the first 24 hours

Very high or uncontrolled blood pressure increases the risk of bleeding and may make treatment unsafe. Current severe uncontrolled hypertension is listed as a contraindication in the prescribing information.

Review for Contraindications and Bleeding Risk

Tenecteplase should not be administered when the risk of serious bleeding outweighs the expected benefit.

FDA-listed contraindications for acute ischemic stroke include:

• Active internal bleeding
• Active bleeding in the brain
• Recent intracranial or spinal surgery or trauma
• A known bleeding disorder
• Severe uncontrolled hypertension
• Certain conditions inside the skull that increase bleeding risk, such as some tumors, vascular malformations or aneurysms

The treating team must also carefully review:

• Current or recent anticoagulant use
• Laboratory results when clinically required
• Recent major surgery or invasive procedures
• Recent gastrointestinal or urinary bleeding
• Recent serious trauma
• Pregnancy
• Liver or kidney disease affecting clotting
• Previous brain bleeding or other conditions that increase hemorrhage risk

Eligibility decisions should follow the current AHA/ASA guideline, FDA prescribing information and the health system’s approved stroke protocol.

Do Not Delay Thrombectomy Evaluation

Tenecteplase does not replace mechanical thrombectomy.

Patients who may have a large-vessel blockage should be evaluated immediately for thrombectomy. Tenecteplase should not delay vessel imaging, specialist consultation, transfer or transport to a thrombectomy-capable center.

Eligible patients may receive tenecteplase before thrombectomy when appropriate. Current guidelines support expanded thrombectomy eligibility for selected patients, including some patients with larger areas of early ischemic injury.

Safe Preparation and Administration

Tenecteplase should be prepared and administered according to the manufacturer’s instructions and the hospital’s pharmacy policy.

Key safety practices include:

• Confirm the patient’s measured weight.
• Confirm that the stroke dosing table is being used.
• Use the supplied sterile water for reconstitution.
• Gently swirl the vial; do not shake it.
• Inspect the solution before administration.
• Administer the calculated dose as one IV bolus over five seconds.
• Discard unused medication.
• Avoid administering it through a line containing dextrose unless the line is flushed with normal saline before and after the dose.

An independent dose verification is strongly recommended because confusing the stroke and heart-attack doses could cause serious harm.

Monitoring After Treatment

Following administration, the patient should receive close neurological, cardiovascular and bleeding surveillance in a stroke unit, intensive care unit or other setting equipped to manage thrombolysis complications.

Monitor for:

• Worsening neurological symptoms
• Severe headache
• Nausea or vomiting
• Sudden increase in blood pressure
• Bleeding from IV, arterial or procedure sites
• Internal bleeding
• Swelling of the tongue, lips or airway
• Allergic or hypersensitivity reactions

Urgent brain imaging is needed when intracranial bleeding is suspected. Tenecteplase can cause serious or fatal internal or external bleeding, and treatment should be limited to facilities able to rapidly evaluate and manage intracranial hemorrhage.

Avoid Unnecessary Procedures

During the early period after tenecteplase:

• Avoid intramuscular injections.
• Limit arterial and venous punctures.
• Avoid noncompressible vascular access sites when possible.
• Apply prolonged pressure to necessary puncture sites.
• Avoid urinary catheters, feeding tubes and invasive procedures unless clinically necessary.
• Coordinate the timing of antiplatelet and anticoagulant medications through the stroke protocol.

The FDA label notes that combining aspirin or heparin with tenecteplase during the first 24 hours after acute ischemic stroke has not been adequately studied and may increase bleeding risk.

Patients With Mild or Improving Symptoms

The decision to treat should be based on whether the remaining symptoms are disabling, not simply whether the symptoms are mild or the NIH Stroke Scale score is low.

Examples of potentially disabling symptoms may include meaningful problems with:

• Speech or language
• Vision
• Walking or balance
• Hand or arm function
• Strength
• Swallowing
• Ability to perform the patient’s normal work or daily activities

For patients with clearly nondisabling symptoms, current AHA/ASA guidance generally favors dual antiplatelet therapy rather than thrombolysis.

System-Level Best Practices

Hospitals using tenecteplase should maintain:

• A written, regularly reviewed stroke thrombolysis protocol
• Standardized inclusion and exclusion criteria
• Stroke-specific dosing charts
• Separate stroke and heart-attack order sets
• Pharmacy and nursing double-check procedures
• Rapid access to neurology and brain imaging
• A plan for hemorrhage and airway emergencies
• Transfer agreements with thrombectomy-capable centers
• Ongoing review of door-to-treatment times, complications and outcomes
• Regular education for emergency, nursing, pharmacy, radiology and EMS teams

Protocols should be reviewed whenever major guidelines, FDA labeling or local stroke-system requirements change.

Important Clinical Notice

This information is intended as an educational overview for health-care professionals. It is not a substitute for the complete FDA prescribing information, current AHA/ASA guidelines, specialist judgment or an institutionally approved stroke protocol. Treatment decisions must be individualized for each patient.